Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
56.6K
-
Shares change
-
0
-
Total reported value, excl. options
-
$61.7K
-
Price
-
$1.09
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q4 2023
1 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q4 2023.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.6K shares
of 229M outstanding shares and own 0.02% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34.9M shares), BlackRock Inc. (8.53M shares), VANGUARD GROUP INC (8.38M shares), Defender Capital, LLC. (4.97M shares), GEODE CAPITAL MANAGEMENT, LLC (2.94M shares), RAFFLES ASSOCIATES LP (2.13M shares), STATE STREET CORP (2.1M shares), Prescott General Partners LLC (1.85M shares), NORTHERN TRUST CORP (1.2M shares), and MAI Capital Management (804K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.